Abstract
Objective
The radiological features of uterine mesenchymal tumors are sometimes similar, which makes differential diagnosis difficult. The aim of meta-analysis was to provide an overview of the literature on the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) or PET/computed tomography (CT) in differentiating between uterine leiomyomas and uterine sarcomas.
Methods
A systematic search of the MEDLINE and EMBASE databases up to June 1, 2021, was performed. All studies that reported the diagnostic accuracy of 18F-FDG PET or PET/CT in differentiating between uterine leiomyomas and uterine sarcomas were considered eligible. Histological confirmation of surgical specimens or clinical confirmation by long-term follow-up examination was considered as the reference standard. Data on diagnostic accuracy were extracted or calculated and presented as forest plots. A bivariate random-effects model was used to calculate pooled estimates of sensitivity and specificity.
Results
A total of seven studies with 196 patients were included for data extraction among initial 507 studies. The overall pooled estimates for sensitivity and specificity were 0.88 [95% confidence interval (CI) = 0.77–0.94] and 0.83 (95% CI = 0.76–0.89), respectively. Likelihood ratio (LR) syntheses yielded an overall positive LR of 4.24 (95% CI = 3.0–6.01) and negative LR of 0.22 (95% CI = 0.13–0.37). The pooled diagnostic odds ratio was 29.59 (95% CI = 12.42–70.49). The area under the hierarchical summary receiver operating characteristic curve was 0.87.
Conclusion
This meta-analysis showed that 18F-FDG PET/CT is a good imaging modality for differentiating between uterine leiomyomas and uterine sarcomas.
Similar content being viewed by others
References
Raine-Bennett T, Tucker L-Y, Zaritsky E, Littell RD, Palen T, Neugebauer R, Axtell A, Schultze PM, Kronbach DW, Embry-Schubert J, Sundang A, Bischoff K, Compton-Phillips AL, Lentz SE (2016) Occult uterine sarcoma and leiomyosarcoma: incidence of and survival associated with morcellation. Obstet Gynecol 127:29–39. https://doi.org/10.1097/aog.0000000000001187
George S, Serrano C, Hensley ML, Ray-Coquard I (2018) Soft tissue and uterine leiomyosarcoma. J Clin Oncol 36:144–150. https://doi.org/10.1200/jco.2017.75.9845
Khan AT, Shehmar M, Gupta JK (2014) Uterine fibroids: current perspectives. Int J Womens Health 6:95–114. https://doi.org/10.2147/ijwh.S51083
Santos P, Cunha TM (2015) Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol 21:4–9. https://doi.org/10.5152/dir.2014.14053
Ha HK, Jee MK, Lee HJ, Choe BY, Park JS, Lee JM, Nam-Koong SE (1997) MR imaging analysis of heterogeneous leiomyomas of the uterus. Front Biosci 2:f4-12. https://doi.org/10.2741/a236
Senapati S, Tu FF, Magrina JF (2015) Power morcellators: a review of current practice and assessment of risk. Am J Obstet Gynecol 212:18–23. https://doi.org/10.1016/j.ajog.2014.07.046
Xu X, Lin H, Wright JD, Gross CP, Boscoe FP, Hutchison LM, Schwartz PE, Desai VB (2019) Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy. J Clin Oncol 37:3412–3424. https://doi.org/10.1200/JCO.19.00562
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K (2008) Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med 22:505–512. https://doi.org/10.1007/s12149-008-0135-2
Park JY, Lee JW, Lee HJ, Lee JJ, Moon SH, Kang SY, Cheon GJ, Chung HH (2017) Prognostic significance of preoperative 18F-FDG PET/CT in uterine leiomyosarcoma. J Gynecol Oncol 28:e28. https://doi.org/10.3802/jgo.2017.28.e28
Ma Y, Shao X, Shao X, Wang X, Wang Y (2016) High metabolic characteristics of uterine fibroids in 18F-FDG PET/CT imaging and the underlying mechanisms. Nucl Med Commun 37:1206–1211. https://doi.org/10.1097/mnm.0000000000000558
Nunes RF, Queiroz MA, Buchpiguel CA, Carvalho FM, Carvalho JP (2019) Aberrant hypermetabolism of benign uterine leiomyoma on 18F-FDG PET/CT. Clin Nucl Med 44:e413–e414. https://doi.org/10.1097/rlu.0000000000002580
Takagi H, Sakamoto J, Osaka Y, Shibata T, Fujita S, Sasagawa T (2018) Utility of 18F-fluorodeoxyglucose-positron emission tomography in the differential diagnosis of benign and malignant gynaecological tumours. J Med Imaging Radiat Oncol. https://doi.org/10.1111/1754-9485.12707
McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH (2018) Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA Statement. JAMA 319:388–396. https://doi.org/10.1001/jama.2017.19163
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982–990. https://doi.org/10.1016/j.jclinepi.2005.02.022
Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20:2865–2884. https://doi.org/10.1002/sim.942
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: http://srdta.cochrane.org/
Ho KC, Dean Fang YH, Lin G, Ueng SH, Wu TI, Lai CH, Chueh HY, Chao A, Chang TC, Yen TC (2018) Presurgical Identification of uterine smooth muscle malignancies through the characteristic FDG uptake pattern on PET Scans. Contrast Media Mol Imaging 2018:7890241. https://doi.org/10.1155/2018/7890241
Kusunoki S, Terao Y, Ujihira T, Fujino K, Kaneda H, Kimura M, Ota T, Takeda S (2017) Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol 56:508–513. https://doi.org/10.1016/j.tjog.2017.05.003
Nagamatsu A, Umesaki N, Li L, Tanaka T (2010) Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep 23:1069–1076. https://doi.org/10.3892/or_00000734
Tsujikawa T, Yamamoto M, Shono K, Yamada S, Tsuyoshi H, Kiyono Y, Kimura H, Okazawa H, Yoshida Y (2017) Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an (18)F-FDG PET/CT texture analysis. Ann Nucl Med 31:752–757. https://doi.org/10.1007/s12149-017-1208-x
Tsujikawa T, Yoshida Y, Mori T, Kurokawa T, Fujibayashi Y, Kotsuji F, Okazawa H (2008) Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET–initial experience. Radiology 248:599–605. https://doi.org/10.1148/radiol.2482071379
Yamane T, Takaoka A, Kita M, Imai Y, Senda M (2012) 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Ann Nucl Med 26:478–484. https://doi.org/10.1007/s12149-012-0597-0
Bulun SE (2013) Uterine fibroids. N Engl J Med 369:1344–1355. https://doi.org/10.1056/NEJMra1209993
Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, Smith J, Addley H, Reinhold C (2019) How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging 100:619–634. https://doi.org/10.1016/j.diii.2019.07.007
Lee SI, Catalano OA, Dehdashti F (2015) Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging. J Nucl Med 56:436–443. https://doi.org/10.2967/jnumed.114.145011
Oldan JD, Patel PS (2016) Positron emission tomography/computed tomography for gynecologic malignancies. Obstet Gynecol Surv 71:545–556. https://doi.org/10.1097/ogx.0000000000000345
Park JY, Lee JW, Lee HJ, Lee JJ, Moon SH, Kang SY, Cheon GJ, Chung HH (2017) Prognostic significance of preoperative 18F-FDG PET/CT in uterine leiomyosarcoma. J Gynecol Oncol 28:e28. https://doi.org/10.3802/jgo.2017.28.e28
Bélissant O, Champion L, Thevenet H, Weinmann P, Alberini JL (2018) Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas. Nucl Med Commun 39:652–658. https://doi.org/10.1097/mnm.0000000000000848
Lee HJ, Park JY, Lee JJ, Kim MH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH (2016) Comparison of MRI and 18F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. Gynecol Oncol 140:409–414. https://doi.org/10.1016/j.ygyno.2016.01.009
Kitajima K, Murakami K, Kaji Y, Sugimura K (2010) Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 195:737–743. https://doi.org/10.2214/ajr.09.4074
Chura JC, Truskinovsky AM, Judson PL, Johnson L, Geller MA, Downs LS Jr (2007) Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review. Gynecol Oncol 104:247–252. https://doi.org/10.1016/j.ygyno.2006.09.024
Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H (2013) 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med 54:499–506. https://doi.org/10.2967/jnumed.112.113472
Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Tsujikawa T, Okazawa H, Tsuchida T, Imamura Y, Suganuma N, Kotsuji F (2008) Comparison of 18F-FDG PET and MRI in assessment of uterine smooth muscle tumors. J Nucl Med 49:708–712. https://doi.org/10.2967/jnumed.107.047142
Dubreuil J, Tordo J, Rubello D, Giammarile F, Skanjeti A (2017) Diffusion-weighted MRI and 18F-FDG-PET/CT imaging: competition or synergy as diagnostic methods to manage sarcoma of the uterus? A systematic review of the literature. Nucl Med Commun 38:84–90. https://doi.org/10.1097/mnm.0000000000000612
Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ (2008) Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 10:745–756. https://doi.org/10.1593/neo.07724
Tsukada H, Muramatsu T, Miyazawa M, Iida T, Ikeda M, Shida M, Hirasawa T, Kajiwara H, Murakami M, Yasuda M, Mikami M (2012) Long term prognostic implications of expression of glucose transporter-1 and hexokinase II in patients with stage I uterine leiomyosarcoma. Acta Histochem Cytochem 45:147–154. https://doi.org/10.1267/ahc.11063
Jehanno N, Wartski M, Malhaire C, Fréneaux P, Petras S, Alberini JL (2014) 18F-FDG PET/CT findings in uterine leiomyomas. Eur J Nucl Med Mol Imaging 41:1034–1035. https://doi.org/10.1007/s00259-014-2698-6
Lerman H, Bar-On S, Helpman L, Even-Sapir E, Grisaru D (2012) Estrogen-dependent variations in 18F-fluorodeoxyglucose uptake in uterine leiomyomas. Int J Gynecol Cancer 22:1187–1191. https://doi.org/10.1097/IGC.0b013e31825bedc7
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Ji-In Bang and Seo Young Kang declare no potential conflicts of interests.
Ethical approval
This manuscript has not been published elsewhere and is not under consideration by another journal. The study protocol was registered to the International Prospective Register of Systematic Reviews (registration No. CRD42021258208).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bang, JI., Kang, S.Y. Diagnostic performance of 18F-FDG PET or PET/CT in differential diagnosis of uterine leiomyomas and uterine sarcomas: systematic review and meta-analysis of the literature. Clin Transl Imaging 10, 301–309 (2022). https://doi.org/10.1007/s40336-022-00488-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-022-00488-7